GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » Research & Development

Pentixapharm Holding AG (XTER:PTP) Research & Development : €8.07 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pentixapharm Holding AG Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Pentixapharm Holding AG's Research & Development for the six months ended in Jun. 2024 was €2.26 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €8.07 Mil.

Pentixapharm Holding AG Research & Development Historical Data

The historical data trend for Pentixapharm Holding AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pentixapharm Holding AG Research & Development Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23
Research & Development
2.89 4.35 8.31

Pentixapharm Holding AG Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24
Research & Development - - 2.49 5.81 2.26

Pentixapharm Holding AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €8.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG  (XTER:PTP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pentixapharm Holding AG Research & Development Related Terms

Thank you for viewing the detailed overview of Pentixapharm Holding AG's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Pentixapharm Holding AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » Research & Development
Comparable Companies
WBO:MARI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170 OCSE:GMAB INSM BMRN HKSE:02269 SHSE:603392 INCY
Traded in Other Exchanges
PTPN:Austria
Address
Robert-Rossle-Street 10, Berlin, DEU
Website
https://www.pentixapharm.com
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Headlines

No Headlines